This is despite the involvement of the PAM pathway in GC disease and the reported preliminary activity of inhibitors both preclinically and in clinical trials33, including Akt inhibitors MK-220634 and ipatasertib11 and the mTOR inhibitor everolimus8,9. Here, AKT1 is linked to gastric cancer.